Early Epcoritamab Administration Revives CAR-T Cells in Relapsed/Refractory B-Cell Lymphomas

被引：0

作者：

Yanashima, Kensuke ^{[1
]}

Furukawa, Yoshiki ^{[1
]}

Ishii, Midori ^{[1
]}

Kinoshita, Shintaro ^{[1
]}

Hamano, Yasuharu ^{[1
]}

Watanabe, Naoki ^{[1
]}

Tsukune, Yutaka ^{[1
]}

Yasuda, Hajime ^{[1
]}

Ando, Jun ^{[1
,2
]}

Ando, Miki ^{[1
]}

机构：

[1] Juntendo Univ, Sch Med, Dept Hematol, Tokyo, Japan

[2] Juntendo Univ, Sch Med, Div Cell Therapy & Blood Transfus Med, Tokyo, Japan

来源：

EJHAEM | 2025年 / 6卷 / 03期

关键词：

EFFICACY;

D O I：

10.1002/jha2.70079

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundBispecific antibodies are effective for relapsed/refractory B-cell lymphoma patients even after CAR-T therapy.MethodsPeripheral blood CAR-T kinetics and functional analysis in vivo were carried out pre- and post-epcoritamab infusion in B-cell lymphoma patients relapsing after CAR-T therapy.ResultsCAR copy numbers spiked at relapse and rose again following epcoritamab administration. Expression levels of CAR-T exhaustion markers did not increase, whereas perforin and granzyme B expression increased after epcoritamab induction.ConclusionEarly epcoritamab administration without cytotoxic agents at relapse after CAR-T therapy revives CAR-T cell numbers and cytotoxicity, which may potentially lead to favorable clinical outcomes.

引用

页数：6

共 12 条

[1] Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas [J].

Chong, Elise A. ;

Penuel, Elicia ;

Napier, Ellen B. ;

Lundberg, Rachel K. ;

Budde, Lihua E. ;

Shadman, Mazyar ;

Matasar, Matthew J. ;

Bartlett, Nancy L. ;

Flinn, Ian W. ;

Bosch, Francesc ;

Fay, Keith ;

Goy, Andre ;

Kumar, Anita ;

Nastoupil, Loretta J. ;

Wei, Michael C. ;

Wu, Mei ;

Yin, Shen ;

Fraietta, Joseph A. ;

Chong, Emeline R. ;

Schuster, Stephen J. .

BLOOD ADVANCES, 2025, 9 (04) :696-703

[2] Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy [J].

Chong, Elise A. ;

Alanio, Cecile ;

Svoboda, Jakub ;

Nasta, Sunita D. ;

Landsburg, Daniel J. ;

Lacey, Simon F. ;

Ruella, Marco ;

Bhattacharyya, Siddharth ;

Wherry, E. John ;

Schuster, Stephen J. .

BLOOD, 2022, 139 (07) :1026-1038

[3]

Elsawy M, 2022, BLOOD, V140, P2248, DOI 10.1182/blood.2022015478

[4] Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma [J].

Harada, Sakiko ;

Ando, Miki ;

Ando, Jun ;

Ishii, Midori ;

Yamaguchi, Tomoyuki ;

Yamazaki, Satoshi ;

Toyota, Tokuko ;

Ohara, Kazuo ;

Ohtaka, Manami ;

Nakanishi, Mahito ;

Shin, Chansu ;

Ota, Yasunori ;

Nakashima, Kazutaka ;

Ohshima, Koichi ;

Imai, Chihaya ;

Nakazawa, Yozo ;

Nakauchi, Hiromitsu ;

Komatsu, Norio .

MOLECULAR THERAPY, 2022, 30 (02) :534-549

[5] T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia [J].

Kalos, Michael ;

Levine, Bruce L. ;

Porter, David L. ;

Katz, Sharyn ;

Grupp, Stephan A. ;

Bagg, Adam ;

June, Carl H. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (95)

[6] Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial [J].

Kamdar, Manali ;

Solomon, Scott R. ;

Arnason, Jon ;

Johnston, Patrick B. ;

Glass, Bertram ;

Bachanova, Veronika ;

Ibrahimi, Sami ;

Mielke, Stephan ;

Mutsaers, Pim ;

Hernandez-Ilizaliturri, Francisco ;

Izutsu, Koji ;

Morschhauser, Franck ;

Lunning, Matthew ;

Maloney, David G. ;

Crotta, Alessandro ;

Montheard, Sandrine ;

Previtali, Alessandro ;

Stepan, Lara ;

Ogasawara, Ken ;

Mack, Timothy ;

Abramson, Jeremy S. .

LANCET, 2022, 399 (10343) :2294-2308

[7] Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo [J].

Milone, Michael C. ;

Fish, Jonathan D. ;

Carpenito, Carmine ;

Carroll, Richard G. ;

Binder, Gwendolyn K. ;

Teachey, David ;

Samanta, Minu ;

Lakhal, Mehdi ;

Gloss, Brian ;

Danet-Desnoyers, Gwenn ;

Campana, Dario ;

Riley, James L. ;

Grupp, Stephan A. ;

June, Carl H. .

MOLECULAR THERAPY, 2009, 17 (08) :1453-1464

[8] Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy [J].

Rentsch, Vera ;

Seipel, Katja ;

Banz, Yara ;

Wiedemann, Gertrud ;

Porret, Naomi ;

Bacher, Ulrike ;

Pabst, Thomas .

CANCERS, 2022, 14 (10)

[9] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].

Schuster, Stephen J. ;

Bishop, Michael R. ;

Tam, Constantine S. ;

Waller, Edmund K. ;

Borchmann, Peter ;

McGuirk, Joseph P. ;

Jaeger, Ulrich ;

Jaglowski, Samantha ;

Andreadis, Charalambos ;

Westin, Jason R. ;

Fleury, Isabelle ;

Bachanova, Veronika ;

Foley, S. Ronan ;

Ho, P. Joy p ;

Mielke, Stephan ;

Magenau, John M. ;

Holte, Harald ;

Pantano, Serafino ;

Pacaud, Lida B. ;

Awasthi, Rakesh ;

Chu, Jufen ;

Anak, Ozlem ;

Salles, Gilles ;

Maziarz, Richard T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :45-56

[10] Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial [J].

Thieblemont, Catherine ;

Phillips, Tycel ;

Ghesquieres, Herve ;

Cheah, Chan Y. ;

Clausen, Michael Roost ;

Cunningham, David ;

Do, Young Rok ;

Feldman, Tatyana ;

Gasiorowski, Robin ;

Jurczak, Wojciech ;

Kim, Tae Min ;

Lewis, David John ;

van der Poel, Marjolein ;

Poon, Michelle Limei ;

Stirner, Mariana Cota ;

Kilavuz, Nurgul ;

Chiu, Christopher ;

Chen, Menghui ;

Sacchi, Mariana ;

Elliott, Brian ;

Ahmadi, Tahamtan ;

Hutchings, Martin ;

Lugtenburg, Pieternella J. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) :2238-+

← 1 2 →